In post-marketing clinical studies, pitavastatin reduced LDL, Total Cholesterol (TC), non-HDL cholesterol and Apolipoprotein B (ApoB) by 26.2-48%, 16.6-37%, 22.5-45%, and 17.4-41%, respectively. Its effects on HDL and triglycerides varied and ranged from -6.9% to 17.8%, and -46% up to an increase of 21%, respectively.